WEEKLY ROUNDUP

The Cocktail Culture Shift Creating a 10X Stock

VIEW IN BROWSER

Hello, Reader.

We’ve officially entered the “ber” months – September, October, November, and December. That means football, tailgates, fall/winter festivities, and holiday cheer.

And that means seasonal beverages, usually made with warming spirits.

A decade ago, few drinkers gave much thought to what mixers went into their gin and tonic or Moscow mule. Spirits commanded the spotlight; mixers stood in the wings like stagehands.

But the company I want to tell you about today has changed that script. By using natural ingredients, elegant packaging, and the aura of connoisseurship, this London-based firm has elevated mixers to costar status.

That repositioning coincided with the rise of the “drink less, but better” ethos. Millennials and Gen Z’ers drink more selectively, favoring higher-quality products with lower alcohol content, or none at all.

The result was a revolution in cocktail culture. Mixers are now mainstage, and this company – Fevertree Drinks PLC (FEVR.L) – has become the brand that successfully delivers them.

On Thursday, the company released its interim earnings report for fiscal year 2025. On the earnings call, CEO Tim Warrillow cited three global trends shaping the brand’s trajectory: premiumization, moderation, and the rise of longer, lighter drinks. Each trend fuels demand for Fever-Tree products – a portfolio that spans tonics, ginger beer, and sodas.

The real headline from the report, however, was the U.S. market. Fever-Tree’s partnership with Molson Coors Beverage Co. (TAP) is no longer a theoretical growth lever; it is an operational reality. The transition into Molson’s 400 distributors is well underway, and while the second half will still be a handover period, early results are strong.

Now, Fever-Tree’s first-half results were not perfect. But analysts minimized cyclical headwinds to cheer the company’s newfound U.S. growth engine. They correctly recognized that the U.S. transformation and margin resilience bode well for future profit growth.

Shares spiked as much as 11% on the results, with RBC, Jefferies, Goodbody, Citi, and JPMorgan all highlighting the U.S. momentum.

Shares have popped nearly 20% since.

This is great news for my subscribers at The Speculator. I recommended the company to readers at my elite-trading service after my new Apogee system signaled a “Buy” alert on it.

Fever-Tree had passed through all of Apogee’s 10X Factors, which means it has the opportunity to reach 1,000% gains.

Over the past week here at Smart Money, I’ve detailed many more details about my Apogee trading system and revealed several other companies that it has identified. (And you can learn even more about it here at my free broadcast.)

Now, let’s get to this week’s Roundup of this week’s Smart Moneyissues.

And then I’ll tell you more about what I expect for Fever-Tree’s future…

Smart Money Roundup

A Growth Story Worth Toasting

Fever-Tree’s recent earnings momentum demonstrates the growing strength of its “cultural moat.”

CEO Warrillow spoke repeatedly of “social occasions” – barbecues, sports events, dinner parties – where Fever-Tree has become embedded. Remember, we’ve recently entered the festive “ber” months.

This cultural embedding is what makes the brand resilient. Competitors can imitate packaging, copy flavors, or undercut on price, but they cannot easily dislodge a brand that has become a cultural default.

Now, the path ahead will not be linear. Spirits categories ebb and flow; weather affects European demand, and execution with Molson will be complex.

But the strategic direction and brand potential are clear: Fever-Tree is becoming a structurally stronger, globally diversified, cash-generative brand.

I expect Fever-Tree to flourish over the coming years.

To stay up-to-date on this intoxicating company, join me at The Speculator today.

Fever-Tree is my most recent Apogee recommendation, but it is far from the last. In fact, all of my recommendations at The Speculator will now come from this breakthrough trading system – with my final vetting, of course. Apogee and I always work together.

That means each new recommendation has the opportunity to reach 1,000% gains, just like Fever-Tree.

Click here to learn more.

Regards,